Table A1.

ACCENT Trials and Number of Patients (With Complete Treatment and Outcome Data) Used for Continuous Time Analyses

Trial	Years	Treatment Arms	No.
MOSAIC	1998-2001	FU + LV v FOLFOX	2,241
XELOXA	2003-2004	FU + LV v XELOX	1,793
N0147*	2004-2009	mFOLFOX6 v mFOLFOX6 + Cetuximab	3,153
C-07	2000-2002	FU + LV v FOLFOX	2,434
C-08	2004-2006	mFOLFOX6 v mFOLFOX6 + bevacizumab	2,612
Total ACCENT			12,233

Abbreviations: ACCENT, Adjuvant Colon Cancer End Points; FOLFOX, fluorouracil, leucovorin, and oxaliplatin; FU, fluorouracil; LV, leucovorin; mFOLFOX6, modified FOLFOX 6 as infusional/bolus fluorouracil, leucovorin, and oxaliplatin; MOSAIC, Adjuvant Treatment of Colon Cancer; XELOX, intravenous oxaliplatin plus oral capecitabine; XELOXA, Adjuvant XELOX.

^*All patients enrolled to N0147 who received FOLFOX were included, regardless of KRAS status.